Quotes 5-day view Delayed Nasdaq
01/23/2023
01/24/2023
01/25/2023
01/26/2023
01/27/2023
Date
1.51(c)
1.45(c)
1.32(c)
1.33(c)
1.33(c)
Last
48 279
113 822
203 579
91 386
121 755
Volume
+0.67%
-3.97%
-8.97%
+0.76%
0.00%
Change
Estimated financial data (e) (USD)
Sales 2022
1,09 M
-
-
Net income 2022
-30,8 M
-
-
Net cash position 2022
45,3 M
-
-
P/E ratio 2022
-2,60x
Yield 2022
-
Sales 2023
0,44 M
-
-
Net income 2023
-34,8 M
-
-
Net cash position 2023
12,9 M
-
-
P/E ratio 2023
-2,28x
Yield 2023
-
Capitalization
80,1 M
80,1 M
-
EV / Sales 2022
31,7x
EV / Sales 2023
152x
Nbr of Employees
34
Free-Float
88,9%
Clearside Biomedical, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering therapies to the back of the eye diseases through the suprachoroidal space (SCS). Its SCS injection platform utilizing its SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted delivery of a variety of therapies to the macula, retina or choroid to preserve and improve...
Ratings of Clearside Biomedical, Inc.
All news about CLEARSIDE BIOMEDICAL, INC.
2022 Clearside Biomedical, Inc.(NasdaqGM:CLSD) dropped fr.. CI
2022 Clearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Con.. AQ
2022 North American Morning Briefing: Fed Hopes, China -3- DJ
2022 Needham Upgrades Clearside Biomedical to Buy Rating From Hold, Price Target is $5 MT
2022 Stifel Upgrades Clearside Biomedical to Buy From Hold, Price Target is $8 MT
2022 Wedbush Lowers Clearside Biomedical's Price Target to $6 From $9, Keeps Outperform Rati.. MT
2022 Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2022 Healthcare Co.. AQ
2022 Clearside Biomedical Retinal Disease Treatment Candidate Meets Primary Endpoint in Phas.. MT
2022 Clearside Biomedical, Inc. : Results of Operations and Financial Condition, Regulation FD .. AQ
2022 Transcript : Clearside Biomedical, Inc., Q3 2022 Earnings Call, Nov 09, 2022 CI
2022 CLEARSIDE BIOMEDICAL, INC. Management's Discussion and Analysis of Financial Condition.. AQ
2022 Clearside Biomedical, Inc. Reports Earnings Results for the Third Quarter and Nine Mont.. CI
2022 Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corpor.. AQ
2022 Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effe.. AQ
2022 Clearside Biomedical, Inc. Announces Positive Results in Safety, Durability and Biologi.. CI
News in other languages on CLEARSIDE BIOMEDICAL, INC.
Analyst Recommendations on CLEARSIDE BIOMEDICAL, INC.
ETFs positioned on CLEARSIDE BIOMEDICAL, INC. ETFs and Trackers with Trackinsight
Chart CLEARSIDE BIOMEDICAL, INC.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends CLEARSIDE BIOMEDICAL, INC.
Short Term Mid-Term Long Term Trends Bullish Neutral Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1,33 $
Average target price
6,40 $
Spread / Average Target
381%
Please enable JavaScript in your browser's settings to use dynamic charts.